

Received: 16 February 2018 Accepted: 23 May 2018 Published online: 07 June 2018

# **OPEN** Temperature-dependent cell death patterns induced by functionalized gold nanoparticle photothermal therapy in melanoma cells

Yujuan Zhang<sup>1,2,5</sup>, Xuelin Zhan<sup>1,2</sup>, Juan Xiong<sup>3</sup>, Shanshan Peng<sup>1,2,4</sup>, Wei Huang<sup>1,2</sup>, Rakesh Joshi<sup>4</sup>, Ying Cai<sup>1,2</sup>, Yanling Liu<sup>1,2</sup>, Rong Li<sup>1</sup>, Keng Yuan<sup>1,2</sup>, Nanjin Zhou<sup>1,2</sup> & Weiping Min<sup>1,2,4</sup>

Photothermal therapy (PTT) is a promising approach for cancer targeting therapy. However, the temperature-dependent killing of tumor cells in PTT remains unclear. In this study, we report necroptosis plays a role in the anti-tumor effects observed in gold nanorod (GNR)-mediated PTT in melanoma. We first synthesized gold nanorods with a targeting adaptor FA (GNRs-FA), which achieved high efficacy of targeted delivery to melanoma cells. We further demonstrated PTT, precipitated by GNRs-FA under the induction of near-infrared laser, was temperature-dependent. Furthermore, the photothermal killing of melanoma cells showed different patterns of cell death depending on varying temperature in PTT. In a lower temperature at 43 °C, the percentages of apoptosis, necroptosis and necrosis of tumor cells were 10.2%, 18.3%, and 17.6%, respectively, suggesting the cell killing is ineffective at lower temperatures. When the temperature increased to 49 °C, the cell death pattern switched to necrosis dominant (52.8%). Interestingly, when the PTT achieved a moderate temperature of 46 °C, necroptosis was significantly increased (35.1%). Additionally, GNRs-FA/PPT-mediated necroptosis was regulated by RIPK1 pathway. Taken together, this study is the first to demonstrate that temperature-dependent necroptosis is an important mechanism of inducing melanoma cell death in GNR-mediated PTT in addition to apoptosis and necrosis.

Cancer, especially solid tumors like melanomas, is the number one health risk to the global population. The traditional methods of cancer therapy include surgery, chemotherapy, and radiotherapy. In most clinical cases, stacked combinations of surgery, chemotherapy and radiotherapy are used to treat tumors and prevent tumor cell metastasis. However, surgery may only remove the macroscopic tumor tissue whereas smaller lesions or pockets of tumor cells may go undetected and escape removal. Surgery is also moot for removing tumor cells already in circulation in the blood or lymphatic system, or those already infiltrated into the surrounding non-cancerous tissue<sup>1</sup>. In contrast, although chemotherapy is a systemic treatment, it has low selectivity for tumor cells, minimal effects on the dormant but transformed tumor cells, and high systemic side effects<sup>1-3</sup>. Radiotherapy is local irradiation that cannot kill non-irradiated parts of tumor and long-term use can lead to an increase of resistance in selected sub-populations of cells due to a loss of sensitivity to radiation<sup>2,3</sup>. Therefore, new therapies for treatment of cancer, including solid tumors, are being developed in recent years.

Photothermal therapy (PTT) is a novel, safe, effective and noninvasive method for the treatment of tumors, which uses external laser light source, irradiating the targeted materials with high photothermal conversion efficiencies to achieve hyperthermia<sup>4-9</sup>. Additionally, tumor-targeting recognition moieties on PTT therapeutics allows them to bio-accumulate in tumor cells with minimal damage to normal cells<sup>4-9</sup>. In terms of induction of optimal PTT and functionalization, gold nanoparticles exhibits localized surface plasmon resonance (LSPR) of

<sup>1</sup>Institute of immunotherapy and College of Basic Medicine of Nanchang University, and Jiangxi Academy of Medical Sciences, Nanchang, China. <sup>2</sup> Jiangxi Provincial Key Laboratory of Immunotherapy, Nanchang, China. <sup>3</sup> Department of Preventive Medicine, School of Medicine, Shenzhen University, Shenzhen, China. <sup>4</sup>Department of Surgery, Pathology and Oncology, University of Western Ontario, London, Canada. <sup>5</sup>Department of Genetics and Complex Diseases, Harvard T.H. Chan School of Public Health, Boston, United States. Yujuan Zhang and Xuelin Zhan contributed equally to this work. Correspondence and requests for materials should be addressed to Y.Z. (email: yujuanzhang@ncu.edu.cn) or W.M. (email: weiping.min@uwo.ca)

free electrons under irradiation of excitatory wavelength laser, which efficiently converts light energy into heat<sup>4-9</sup>. The surface plasmon resonance peak of gold nanorods (GNRs) can be tuned into the near- infrared (NIR) spectra<sup>4,6</sup>. NIR light is reported to penetrate into the subcutaneous cell layer up to a depth of 10 mm to a few centimeters<sup>10</sup>. Therefore, GNR is widely being used in PTT treatment of tumors<sup>4,6</sup>. After tumor-targeting modification, the PTT effects of GNRs can selectively increase the temperature of tumor tissue to 50 °C to 70 °C, exceeding the threshold that leads to the death of tumor cells and tumor-encapsulating blood vessels<sup>11,12</sup>.

However, the mechanism of GNRs-mediated PTT killing tumor cells remains unclear. Previous studies have shown that GNR-mediated PTT caused apoptosis and necrosis of tumor cells, which is associated with the induced temperature by PTT<sup>13,14</sup>. Recently, a new type of cell death termed necroptosis was identified as a novel cell death mechanism<sup>15,16</sup>. It has also been reported that necroptosis occurs in tumor cells after heat treatment *in vitro*<sup>17,18</sup>, and also could be induced by PTT in cervical cancer cell lines<sup>19</sup>. Recent studies have investigated the occurance of necroptosis in melanomas, especially those mediated via the mitochondria-dependent ROS-generation and induction of mitophagy/autophagy<sup>20–22</sup>. Interestingly, the cytoplasmic RIPK3 serine/threonine kinase has also been implicated in necroptic cell death of melanomas, but not the related RIPK1 pathway<sup>23</sup>. Furthermore, PTT therapy and the induction of necroptosis in cancer has also been investigated, including using gold nanoparticles<sup>19,24–26</sup>. Moreover, there is a wealth of pre-clinical studies supporting the justification of applying PTT in cancers, including melanomas<sup>19,24–29</sup>. However, investigations into temperature-dependence of necroptosis and effects in melanomas are lacking. Additionally, the relationship between temperature and necroptosis has not been clarified in spite of increased temperature serving as the critical element for PTT killing tumor cells<sup>11,14</sup>. Therefore, it is extremely essential to investigate the relationship between the raised temperature of PTT and necroptosis of tumor cells. In this study, we firstly investigate the influence of increased temperature on cell death in melanomas, including necroptosis for this phenomenon of GNR-mediated PTT.

## **Materials and Methods**

**Cell lines.** A murine melanoma cell line B16-BL6 was obtained from the American Type Culture Collection (ATCC) and maintained in DMEM medium (Life Technologies, Carlsbad, CA) with 10% FBS at 37 °C in 5% CO<sub>2</sub>.

**Synthesis of GNR.** HAuCl<sub>4</sub> was acquired from SinoPharm (Shanghai Chemical Reagent Co., Ltd). Water-soluble gold nanorods were synthesized via seed-mediated growth routes as previously described<sup>30</sup>. Briefly, a seed solution was first prepared as follows: 1 ml of cetyltrimethylammoniumbromide (CTAB) (Sinopharm) solution (0.2 M) was mixed with 1 ml of HAuCl<sub>4</sub> (0.5 mM) (Sinopharm). While the solution was stirred at 28 °C, 0.12 ml of ice-cold 0.01 M NaBH<sub>4</sub> (Sinopharm) was added, until the resulting seed solution turned to brownish yellow color. Subsequently,the growth solution was prepared as follows: 50 ml of HAuCl<sub>4</sub> (1 mM), 50 ml of CTAB (0.2 M) and 2.5 ml of AgNO<sub>3</sub> (Sinopharm) (4 mM) were gently mixed at 28 °C, and 670 µl of ascorbic acid (0.079 M) was added until the color changed from dark yellow to colorless. To generate gold nanorods, 120 µl of the seed solution was added to the growth solution at 28 °C with gentle stirring. Within 30 min, the combined solution gradually changed color to brownish red. After 24 hrs, the solution was centrifuged at 12,000 rpm for 10 mins to remove the excessive CTAB and vacuum freeze-dried to a powder of GNR.

**Synthesis of PEI-MUA and FA-PEI-MUA.** Mercaptoundecanoic acid (MUA; 654 mg) was added to 30 ml carbon tetrachloride ( $\rm CCl_4$ ), followed by addition of 100 mmol 1-ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride (EDC) and 100 mmol N-Hydroxysuccinimide (NHS) at room temperature for 15 min. 100 mmol polyethylene imine (PEI) was added to the above solution at room temperature for 12 hrs. An equal volume of de-ionized water was added for extraction of water-soluble PEI-MUA. The same method was used to complete the activation of folic acid in aqueous solution. Briefly, the above water-soluble PEI-MUA solution was added in the same molar ratio with folic acid and reacted at room temperature for 12 hrs to obtain water-soluble FA-PEI-MUA complex.

**Synthesis of PEI-GNR and FA-GNR.** GNR powder (HAuCl<sub>4</sub>; 10 mg) was added to 10 ml of the above water-soluble PEI-MUA or FA-PEI-MUA complex and stirred at room temperature for 12 hrs. The CTAB was successfully replaced by Au-S bond. An aqueous solution of PEI-GNR or FA-GNR was obtained by lyophilization, weighed and dissolved in non-ribozyme water. The plasma resonance effect was observed by a multifunctional microplate reader (SpectraMax M5e, MD, USA).

**Transmission electron microscopy (TEM).** One drop of GNR or FA-GNR complex was placed on a copper grid and allowed to dry for 10 min before examination with an electron microscope. The morphology of GNR and FA-GNR complexes were observed using TEM (LIBRA 120, Carl Zeiss, Germany).

**UV-Vis assay.** The vacuum freeze-dried GNR, PEI-GNR, and FA-GNR were prepared into a 1 mg/ml homogeneous suspension, which was detected by a microplate reader (SpectraMax M5e, MD, USA) for surface plasmon resonance effect at wavelength ranges of 650 nm to 900 nm.

Cellular uptake efficiencies of GNRs-FA. B16-BL6 cells were plated in 24-well microplates at a density of  $1\times10^5$  cells/ml. After 24 hrs, the medium was replaced with  $200\,\mu$ l  $50\,\mu$ g/ml GNR-PEI/siRNA (wt(GNR-PEI): wt(siRNA) = 32:1),  $50\,\mu$ g/ml GNR-FA/siRNA (wt(GNR-FA): wt(siRNA) = 32:1) or PBS/siRNA as control which were conjugated with the same amount Cy3-siRNA ( $0.66\,\mu$ g). The nanocarriers were incubated with cells at  $37\,^{\circ}$ C for 24 hrs. The cells were washed three times with PBS to remove unloaded nanoparticles and the images were taken with inverted and fluorescence microscopes. Cells were then trypsinized, harvested, washed three times with PBS to remove unloaded nanoparticles and resuspended in 200 ml of the medium and analyzed by flowcytometry Calibur (BD FACS Excalibur, BD Biosciences, Mountain View, CA).




Figure 1. Synthesis, modification and cellular uptaking efficiencies of GNRs-FA. (A) TEM image of GNR after modification with folic acid (scale bar = 100 nm); (B) Normalized UV-Vis absorption spectra of un modified GNR or GNRs-PEI (GNRs-MUA-PEI), or GNRs-FA (GNRs-MUA-PEI-FA); (C,D) Transfection efficiency of Cy3-siGAPDH by PBS (control), and nanocarriers GNRs-PEI and GNRs-FA. After 24 hrs incubation, the Cy3 positive population of B16-BL6 was determined by flow cytometry (C), and the intracellular Cy3 fluorescence was imaged by brightfield and fluorescence microscope (D) (scale bar =  $50\,\mu m$ ). Error bars represent the standard deviation of 3 experiments.

**GNR photothermal effects** *in vitro*. B16-BL6 cells were cultured ( $200\,\mu l\,4 \times 10^4$ /ml; log phase) in a 96-well plate. After 24 hrs, the B16-BL6 cells were treated with  $50\,\mu g/ml$  GNRs-FA or PBS as control for another 24 hrs. NIR laser irradiation ( $808\,nm$ ) was conducted at the varied conditions (Current (A) levels  $0.55\,A$  ( $0.956\,W$ ),  $0.60\,A$  ( $1.275\,W$ ) and  $0.65\,A$  ( $1.593\,W$ )) was applied for 15 min. The laser beam targeting of specific wells in the 96-well format plates was controlled by a filter paper cover. To monitor the temperature, the laser beam was moved away, and the temperature was detected with an infrared radiation thermometer (VT02 Visual IR Thermometer, Fluke, USA) that was vertically placed at 5 cm above the target well for taking the thermal heat map very quickly ( $\sim$ 2 Secs), and then the laser beam was moved back again.

PTT causing the pattern of cell death assessed by MTT assay. B16-BL6 cells ( $200\,\mu l\,4\times10^4/ml$ ; log phase) were cultured in a 96-well plate. After 24 hrs, the cells were treated in the cell culture medium with 50  $\mu g/ml$  GNRs-FA or PBS as control for another 24 hrs. Caspase- or RIPK1- inhibitors Z-VAD or Nec-1 was added into the wells in final concentrations of 20  $\mu$ M or with PBS as control for 4 hrs. The 808 nm NIR laser irradition at the above indicated conditions was applied for 15 min. After 24 hrs, the MTT reagent was added for another 4 hrs for conversion by mitochondrial reductase. The resulting purple crystals were dissolved in solubilization buffer and analyzed by spectrophotometry at 490 nm, using a reference of 650 nm in a microplate reader (SpectraMax M5e, MD, USA).

**Statistics.** Data were presented as mean  $\pm$  SD. Student's t-test (2-tailed) was applied to determine differences between two means. For the comparison of multiple groups, one-way ANOVA test was used. For all statistical analyses, differences with p values < 0.05 were considered significant.

## Results

**Synthesis, modification and cellular uptake efficiencies of GNRs-FA.** In order to make GNR-FA, we first synthesized GNR and then modified it with MUA-PEI (GNR-PEI) and conjugated with a tumor-targeting adaptor folic acid (FA in GNR-FA). The morphologies of GNRs-PEI and GNRs-FA were detected by TEM image (Fig. 1A). The dimensions of the GNRs were  $10\pm2.3\,\mathrm{nm}$  in radius and  $40\pm3.6\,\mathrm{nm}$  in length, with an average aspect ratio of 4.0. After modifications, normalized UV-Vis absorption demonstrated a spectra shift between unmodified GNR and modified GNRs-PEI (GNR-MUA-PEI) or GNRs-FA (GNR-MUA-PEI-FA) (Fig. 1B).






Figure 2. Temperature increase induced by laser-treatment of GNRs-FA. B16-BL6 cells were treated with PBS or  $50\,\mu\text{g/ml}$  GNRs-FA for 24 hrs. (A) A filter paper, with a well-sized hole for a 96-well format plate, was used to cover the treated cells to guarantee the laser irradiating the target well accurately, and an infrared radiation thermometer was applied to measure the temperature; (B) An 808 nm near infrared laser source was applied for 15 min with different power densities that could be adjusted by the current (0.55A (a), 0.60A (b), 0.65A (c)). The detected temperature (converted to Celsius) was plotted. Results represent 1 of 3 experiments.

To test the targeted transfection efficiency of the nanoconstructs, we transfected the melanoma cell line B16-BL6 using modified GNRs that were pre-conjugated with fluorescent dye Cy3-labeled siRNA. After 24 hrs incubation, the Cy3-positive population of cells was determined by flow cytometry. Whereas non-FA targeted GNR-PEI only showed about 36.5% transfection efficacy, FA targeted transfection using GNR-FA achieved transfection efficiencies as high as 96.0% (Fig. 1C). To visually validate the intracellular uptake of Cy3-labeled siRNA transfected by nanocarriers GNR-PEI and GNR-FA, we also assessed them with brightfield and fluorescence microscopy. The intracellular fluorescence intensity in the B16-BL6 cells transected by tumor-targeted GNRs-FA was remarkably increased as compared with the cells transfected by non-targeted GNRs-PEI (Fig. 1D). These data suggested that the synthesis of GNRs-FA was successful and the targeted delivery using FA modification of GNR can achieve higher efficacies of transfection into tumor cells.

**Temperature increase induced by photothermal effects of GNRs-FA.** Our previous study has demonstrated that GNR can produce heat under the irradiation of near infrared laser, a phenomenon called photothermal effect due to LSPR properties of the GNR. To test whether GNRs-FA can introduce efficient photothermal effects, we cultured B16-BL6 cells and transfected them with GNRs-FA, followed by the near infrared laser (808 nm) irradiation (Fig. 2A). The temperature of irradiated wells containing the cells was detected using an infrared radiation thermometer. As shown in Fig. 2B, effective photothermal effects were successfully induced by GNRs-FA under a current from 0.55A to 0.65A of laser irradiation. After 15 min with different power densities of laser power at 0.55A (Figs. 2B(a)), 0.60A (Fig. 2B(b)) and 0.65A (Fig. 2B(c)), the temperatures were increased up to 43 °C, 46 °C and 49 °C, respectively. These data implied that the increase in temperature is time- and also current-dependent, which can be controlled by adjusting the current.

**Temperature-dependent cell death patterns induced by photothermal effects of GNRs-FA in melanoma tumor cells.** Photothermal treatment (PPT) produces a hyperthermal microenvironment in tumor sites, which kill tumor cells through induction of necrosis or apoptosis <sup>13,14</sup>. Recent studies report a new mechanism of cell death called necroptosis <sup>15,16</sup>. To investigate whether GNR-FA treatment is capable of inducing necroptic death in melanoma cells, we set up an experiment using a controlled amount laser beam and current






**Figure 3.** Temperature-dependent cell cytotoxicity patterns of tumor cells by GNR-mediated photothermal therapy. (**A**) B16-BL6 cells were treated GNRs-FA or PBS as control for 24 hrs. Additionally, caspase or RIPK1 inhibitor, Z-VAD or Nec-1 was implemented for 4 hrs. Finally, the cells were irradiated with laser (15 min), and cytotoxicities were evaluated by MTT assay; (**B**) (a) Cell viability (%) in each control group, and (b) cell death (%) in different treatment types were calculated; (**C**) The percentages of live, apoptotic, necroptotic, and necrotic cells at different temperature treatments (43 °C, 46 °C, 49 °C) after PTT with respective laser dosages (0.55A, 0.60A, 0.65A for 15 min). Error bars represent the standard deviation of 3 experiments (n = 3 per group/experiment).

intensity in order to induce temperature-dependent PTT in BL6-B16 melanoma cells (Fig. 2A). It has been reported that RIPK1-RIPK3-MLKL pathway is critical in induction of necroptosis<sup>31</sup>. To clarify the patterns of cell death after GNR-FA induced PTT, we treated the tumor cells with GNRs-FA and inhibitors first and then followed by laser irradiations as in Fig. 2B at three temperature levels: low (43 °C), medium (46 °C), high (49 °C).

To validate whether necroptosis and/or apoptosis are involved in the tumor killing mediated by PTT of GNRs-FA, we treated B16-BL6 using GNRs-FA or PBS, in the presence of RIPK1 inhibitor Nec-1 that blocks necroptosis pathways<sup>31,32</sup>. We also used pan-caspase inhibitor Z-VAD to block the apoptotic pathway<sup>33</sup>. After irradiation using the 808 nm NIR laser at three conditions, the cell viabilities were assessed using the MTT assay (Fig. 3A). As shown in Fig. 3B(b), the percentage of cell death decreased to 46.1% at 43 °C from 81.3% at 46 °C, and increased to 86.3% at 49 °C after the treatment with different laser doses. After, blocking necroptosis by adding Nec-1, the percentages of cell death after GNRs-FA mediated PPT at corresponding laser doses significantly dropped at low temperature (from 46.1% to 28.5%), at medium temperature (from 81.3% to 46.2%), and at high temperature (from 86.3% to 74.6%) (Fig. 3B(b)). Similar reductions were also observed when blocking the apoptosis pathway using Z-VAD, although the decreases were less at a low temperature but stronger at higher temperatures (Fig. 3B(b)).

Percentages of live, apoptotic, necroptotic, and necrotic cells at different temperatures (43 °C, 46 °C, 49 °C) adjusted for PTT with increasing laser doses (0.55A, 0.60A, 0.65A) for 15 min are calculated in Fig. 3(C). PTT kills tumor cells mainly through necroptosis and apoptosis when the induced temperature is 46 °C. Apoptosis, but especially necrosis, are the primary mechanisms for PTT-induced cell dath of melanoma tumor cells when the induced temperature is high (49 °C). In contrast, most tumor cells (53.9%) survived when the induced



**Figure 4.** Schematic of proposed mechanism of photothermal therapy (PTT) action against tumor cells. PTT kills tumor cells mainly through necroptosis and apoptosis when the induced temperature reaches around 46 °C. Necrotic pathway is the major mechanistic pathway for PTT killing tumor cells at a higher temperature (49 °C). In contrast, most of tumor cells will survive when the induced temperature is lower than 43 °C. Error bars represent the standard deviation of 3 experiments (n = 3 per group/experiment).

temperature is lower (43 °C (Fig. 3(C)). These data highlighted that GNR-FA induced tumor killing pattern in PPT is temperature-dependent and necroptosis regulated by RIPK1 pathway plays an important role in the killing of melanoma tumor cells by the GNRs-FA nano-construct. A proposed mechanism of photothermal therapy killing tumor cells is presented as a schematic in Fig. 4. This study provides evidence in helping us understand the mechanism of PTT killing tumor cells. RIPK1-mediated necroptosis is the other vital mechanism of photothermal therapy killing tumor cells, in addition to apoptosis and necrosis.

# Discussion

Photothermal therapy (PTT) is a novel, safe, effective and non-invasive method for the treatment of tumors when compared to the traditional cancer therapy methods of surgery and chemotherapy. Gold nanorod (GNR)-aided PTT, using near-infrared laser, enhances irradiation of tumors with higher photothermal conversion efficiency. GNR functionalized with tumor-targeting recognition moieties help it to accumulate in tumor cells, increasing the temperature-dependent cytotoxicity to the tumor cells, with minimal damage to normal cells<sup>4-9</sup>. Since 2005, due to the discovery of unique optical properties of gold nanoparticles (GNP) and their ability to exhibit localized surface plasmon resonance (LSPR) of free electrons under laser irradiation, GNR is widely used in PTT treatment of tumors<sup>4-9</sup>. El-Sayed *et al.* (2006) reported for the first time that gold nano-spheres with anti-EGFR monoclonal antibodies can target to kill malignant tumor cells by PTT *in vitro*<sup>5</sup>. Similarly, in 2011, Drezek *et al.* demonstrated that PTT specifically inhibited drug-resistant breast cancer cells (JIMT-1) *in vitro* by using HER2 monoclonal antibody-modified core/shell of SiO<sub>2</sub>/Au nanostructure<sup>34</sup>. We developed a new tumor-targeting FA-GNR construct and used it to evaluate anti-cancer effects on melanoma cells based on the photothermal effects for PTT<sup>35</sup>. In this study, we further investigated the anti-tumor mechanism on melanoma cells by PTT.

The surface plasmon resonance peak of gold nanorods (GNRs) can be tuned into the NIR band (700–1300 nm) by changing the aspect ratio of nanorod so as to reduce the emitted laser energy and increase the transmission depth  $^{10}$ . After targeted modification, the PTT effects of GNRs can selectively increase the temperature of tumor tissue to 50 °C or even 70 °C, exceeding the threshold that leads to the death of tumor blood vessels or tumor cells  $^{11,12}$ . PTT was demonstrated to be a promising anti-tumor approach, which also effectively killed drug-resistant cancer cells  $^{34,36}$ . PTT, using gold nanoparticles, PEG-based nanoparticles and carbon nanotubes have all been used in pre-clinical studies, including for melanomas  $^{22,25,27}$ . PTT using gold nanoparticles for various cancers are also in clinical trials. Gold nanoparticles with thiolated PEG and tumour necrosis factor- $\alpha$  (TNF- $\alpha$ ) (CYT-6091; Aurimmune; CytImmune Sciences, Rockville, MD), have entered early clinical trials. A single-dose pilot study of AuroShell® particles (Nano- spectra Biosciences, Inc., Houston, TX) given intravenously to patients with recurrent or refractory head and neck cancer is in progress  $^{37}$ . It has been reported in the past that PTT killing tumor cell is temperature-dependent, however the mechanism of cell death, necrosis, apoptosis or necroptosis, and temperature dependence has never been explored previously. Moreover, a targetable pathway, such as the RIPK pathway, in melanomas remains un-investigated. High temperatures (higher than

 $50\,^{\circ}\text{C}$ ) primarily lead directly to necrosis, but lower ranges (below about  $50\,^{\circ}\text{C}$ ) primarily induce cell apoptosis  $^{11,14,38}$ . For PTT applications, the range of therapy temperature is normally lower than  $50\,^{\circ}\text{C}$  for causing less cell necrosis less inflammation and also protecting normal cells from high temperature surrounding  $^{11,14,38}$ . So in this study, we selected three temperatures: low temperature (43  $^{\circ}\text{C}$ ), medium temperature (46  $^{\circ}\text{C}$ ), and high temperature (49  $^{\circ}\text{C}$ ). However, the temperature dependence of new cell death mechanism necroptosis by PTT was firstly explored in this paper.

In recent years, a number of studies reported that GNR-mediated PTT can effectively inhibit the growth of tumors in mice, and the biological safety study of GNRs showed that normal mice did not display the functional damage and pathological lesions in the heart, liver, spleen, kidney, and lung after long-term therapy with GNR<sup>38</sup>. Our study found that percentages of survival cells were high about 53.7% at low temperature (43 °C). The lethality was apparently raised when the temperature induced by PTT was 46 °C (percentages: 18.7% live, 31.8% apoptosis, 35.1% necroptosis, 14.4% other (necrosis)), and most cells (66.9%) were killed via apoptosis and necroptosis. When the temperature was increased to 49 °C, the percentages of apoptosis and necroptosis dropped significantly, and most of cells (52.8%) were killed through necrosis, which is also indicated by previous studies <sup>11,14,38</sup>.

In addition, gold nanorods are also effective drug-targeting transporters. Nano drug delivery system has the advantages of improving physical and chemical properties, stability, pharmacokinetics and pharmacology and toxicology of the drug and achieve better sustained drug release, targeting and therapeutic effects<sup>39,40</sup>. The current research shows that gold nanorods not only can effectively load drugs but also possess the advantages of easy modification (such as targeting modifications and biological compatibility modifications) and infrared laser-induced surface plasmon resonance which can also assist drug release<sup>41,42</sup>. We has previously synthesized folic acid-functionalized gold nanorods capable of carrying small RNA molecules and have demonstrated that it is effective in protecting siRNAs from RNase in sera, can target folate-overexpressing tumors cells (such as melanoma, lung cancer, and breast cancer) and silence various genes (BRAF and IDO)<sup>35</sup>. GNR-mediated PTT combined with siRNA, miRNA and other therapeutic technologies can significantly enhance the anti-tumor effects, which opens a promising Oncotherapeutic field<sup>35,43</sup>.

However, the mechanism of GNR-mediated PTT killing tumor cells remains unclear. Since the 1990s, it has been discovered that the use of a pan-caspase inhibitor or knockout of caspase 8, TNF- $\alpha$  and FasL, no longer induces apoptosis in cells but causes necrosis<sup>44</sup>. In 2005, this type of necrosis, which is initiated by a specific factor and follows certain pathways and mechanisms, was named programmed necrosis or necroptosis<sup>45</sup>. Since 2009, the major necroptosis-activating signaling pathways have gradually been elucidated, mainly by phosphorylated RIPK1 and RIPK3 activating MLKL31. It was shown that the phosphorylated MLKL translocates to the cell membrane resulting in disruption of cell membrane integrity and the release of intracellular molecules that are pro-inflammatory<sup>31</sup>. Necroptosis accelerated the death of tumor cells and increased the sensitivity of tumor cells to anti-tumor treatment, and also killed the drug resistant tumor cells caused by dysfunction of cell apoptosis 46,47. Parida et al. reported that GNRs bring about photothermal effect under NIR, leading to hyperthermic death to cervical cancer cells by necroptosis enhancing the anti-tumor effects of chemotherapeutic drug GW627368X, a selective, prostanoid EP4 inhibitor<sup>19</sup>. Therefore, necroptosis is an important but uncharacterized cell death mechanism, although there have been a few previous reports on tumor cell necroptosis after heat treatment in vitro or PTT<sup>17-19</sup>. This study is the first direct demonstration that temperature-dependent necroptosis is an important mechanism of inducing melanoma cell death in GNR-mediated PTT, in addition to apoptosis and necrosis. More importantly, although immunotherapeutic approaches are viable strategies for malignant melanoma therapy, the literature and our current and previous studies also demonstrated that PTT could also produce an "abscopal effect"<sup>24,48</sup>, which is beneficial for immunotherapy leading to a synergistic anti-tumor regimens.

#### References

- 1. Mazzaferri, E. L. & Jhiang, S. M. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. *The American journal of medicine* **97**, 418–428 (1994).
- 2. Recht, A. et al. The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. New England Journal of Medicine 334, 1356–1361 (1996).
- 3. Tepper, J., Nardi, G. & Suit, H. Carcinoma of the pancreas: review of MGH experience from 1963 to 1973—analysis of surgical failure and implications for radiation therapy. *Cancer* 37, 1519–1524 (1976).
- 4. Dickerson, E. B. et al. Gold nanorod assisted near-infrared plasmonic photothermal therapy (PPTT) of squamous cell carcinoma in mice. Cancer letters 269, 57–66 (2008).
- El-Sayed, I. H., Huang, X. & El-Sayed, M. A. Selective laser photo-thermal therapy of epithelial carcinoma using anti-EGFR antibody conjugated gold nanoparticles. Cancer letters 239, 129–135 (2006).
- Huang, X., El-Sayed, I. H., Qian, W. & El-Sayed, M. A. Cancer cell imaging and photothermal therapy in the near-infrared region by using gold nanorods. *Journal of the American Chemical Society* 128, 2115–2120 (2006).
- 7. Huang, X. & El-Sayed, M. A. Gold nanoparticles: optical properties and implementations in cancer diagnosis and photothermal therapy. *Journal of advanced research* 1, 13–28 (2010).
- 8. Huang, X., Jain, P. K., El-Sayed, I. H. & El-Sayed, M. A. Plasmonic photothermal therapy (PPTT) using gold nanoparticles. Lasers in medical science 23, 217 (2008).
- Kim, J. et al. Designed fabrication of multifunctional magnetic gold nanoshells and their application to magnetic resonance imaging and photothermal therapy. Angewandte Chemie 118, 7918–7922 (2006).
- 10. Weissleder, R. A clearer vision for in vivo imaging. Nature biotechnology 19, 316-317 (2001).
- 11. Huang, X., Jain, P. K., El-Sayed, I. H. & El-Sayed, M. A. Determination of the minimum temperature required for selective photothermal destruction of cancer cells with the use of immunotargeted gold nanoparticles. *Photochemistry and photobiology* 82, 412–417 (2006).
- 12. Mackey, M. A., Ali, M. R., Austin, L. A., Near, R. D. & El-Sayed, M. A. The most effective gold nanorod size for plasmonic photothermal therapy: theory and *in vitro* experiments. *The Journal of Physical Chemistry B* 118, 1319–1326 (2014).
- 13. Ali, M. R., Ali, H. R., Rankin, C. R. & El-Sayed, M. A. Targeting heat shock protein 70 using gold nanorods enhances cancer cell apoptosis in low dose plasmonic photothermal therapy. *Biomaterials* 102, 1–8 (2016).
- 14. Pérez-Hernández, M. et al. Dissecting the molecular mechanism of apoptosis during photothermal therapy using gold nanoprisms. ACS nano 9, 52–61 (2014).

- Christofferson, D. E. & Yuan, J. Necroptosis as an alternative form of programmed cell death. Current opinion in cell biology 22, 263–268 (2010).
- 16. Galluzzi, L. & Kroemer, G. Necroptosis: a specialized pathway of programmed necrosis. Cell 135, 1161-1163 (2008).
- 17. Mouratidis, P. X., Rivens, I. & ter Haar, G. A study of thermal dose-induced autophagy, apoptosis and necroptosis in colon cancer cells. *International Journal of Hyperthermia* 31, 476–488 (2015).
- 18. Thompson, S. M. et al. Heat stress induced cell death mechanisms in hepatocytes and hepatocellular carcinoma: in vitro and in vivo study. Lasers in surgery and medicine 46, 290–301 (2014).
- Parida, S. et al. Gold nanorod embedded reduction responsive block copolymer micelle-triggered drug delivery combined with photothermal ablation for targeted cancer therapy. Biochimica et Biophysica Acta (BBA)-General Subjects 1861, 3039–3052 (2017).
- 20. Basit, F. et al. Mitochondrial complex I inhibition triggers a mitophagy-dependent ROS increase leading to necroptosis and ferroptosis in melanoma cells. Cell Death Dis 8, e2716, https://doi.org/10.1038/cddis.2017.133 (2017).
- 21. Hammerova, J., Uldrijan, S., Taborska, E., Vaculova, A. H. & Slaninova, I. Necroptosis modulated by autophagy is a predominant form of melanoma cell death induced by sanguilutine. *Biol Chem* 393, 647–658, https://doi.org/10.1515/hsz-2011-0279 (2012).
- 22. Sonkusre, P. & Cameotra, S. S. Biogenic selenium nanoparticles induce ROS-mediated necroptosis in PC-3 cancer cells through TNF activation. J Nanobiotechnology 15, 43, https://doi.org/10.1186/s12951-017-0276-3 (2017).
- 23. Geserick, P. et al. Absence of RIPK3 predicts necroptosis resistance in malignant melanoma. Cell Death Dis 6, e1884, https://doi.org/10.1038/cddis.2015.240 (2015).
- 24. Bear, A. S. et al. Elimination of metastatic melanoma using gold nanoshell-enabled photothermal therapy and adoptive T cell transfer. PLoS One 8, e69073, https://doi.org/10.1371/journal.pone.0069073 (2013).
- 25. Mendes, R., Pedrosa, P., Lima, J. C., Fernandes, A. R. & Baptista, P. V. Photothermal enhancement of chemotherapy in breast cancer by visible irradiation of Gold Nanoparticles. *Sci Rep* 7, 10872, https://doi.org/10.1038/s41598-017-11491-8 (2017).
- Wang, H. et al. Aspect ratios of gold nanoshell capsules mediated melanoma ablation by synergistic photothermal therapy and chemotherapy. Nanomedicine 12, 439–448, https://doi.org/10.1016/j.nano.2015.11.013 (2016).
- Jiang, B. P. et al. Poly(N-phenylglycine)-Based Nanoparticles as Highly Effective and Targeted Near-Infrared Photothermal Therapy/ Photodynamic Therapeutic Agents for Malignant Melanoma. Small 13, https://doi.org/10.1002/smll.201602496 (2017).
- 28. Sobhani, Z., Behnam, M. A., Emami, F., Dehghanian, A. & Jamhiri, I. Photothermal therapy of melanoma tumor using multiwalled carbon nanotubes. *Int J Nanomedicine* 12, 4509–4517, https://doi.org/10.2147/IJN.\$134661 (2017).
- 29. Yu, Q. et al. Copper Silicate Hollow Microspheres-Incorporated Scaffolds for Chemo-Photothermal Therapy of Melanoma and Tissue Healing. ACS Nano 12, 2695–2707, https://doi.org/10.1021/acsnano.7b08928 (2018).
- Nikoobakht, B. & Mostafa, A. E. Preparation and growth mechanism of gold nanorods (NRs) using seed-mediated growth method. Chemistry of materials: a publication of the American Chemical Society 15, 1957–1962 (2003).
- 31. Linkermann, A. & Green, D. R. Necroptosis. New England Journal of Medicine 370, 455-465 (2014).
- 32. Degterev, A., Maki, J. & Yuan, J. Activity and specificity of necrostatin-1, small-molecule inhibitor of RIP1 kinase. *Cell death and differentiation* 20, 366 (2013).
- 33. Huijun, Z., MacFARLANE, M., NICHOLSON, D. W. & COHEN, G. M. Benzyloxycarbonyl-Val-Ala-Asp (OMe) fluoromethylketone (Z-VAD. FMK) inhibits apoptosis by blocking the processing of CPP32. *Biochemical Journal* 315, 21–24 (1996).
- 34. Carpin, L. B. *et al.* Immunoconjugated gold nanoshell-mediated photothermal ablation of trastuzumab-resistant breast cancer cells. *Breast cancer research and treatment* **125**, 27–34 (2011).
- 35. Zhang, Y. et al. Synergic therapy of melanoma using GNRs-MUA-PEI/siIDO2-FA through targeted gene silencing and plasmonic photothermia. RSC Advances 6, 77577–77589 (2016).
- 36. Zhang, W. et al. pH and near-infrared light dual-stimuli responsive drug delivery using DNA-conjugated gold nanorods for effective treatment of multidrug resistant cancer cells. Journal of Controlled Release 232, 9–19 (2016).
- 37. Jain, S., Hirst, D. G. & O'Sullivan, J. M. Gold nanoparticles as novel agents for cancer therapy. *Br J Radiol* 85, 101–113, https://doi.org/10.1259/bjr/59448833 (2012).
- 38. Ali, M. R. et al. Efficacy, long-term toxicity, and mechanistic studies of gold nanorods photothermal therapy of cancer in xenograft mice. Proceedings of the National Academy of Sciences, 201619302 (2017).
- 39. Kumari, A., Yadav, S. K. & Yadav, S. C. Biodegradable polymeric nanoparticles based drug delivery systems. *Colloids and Surfaces B: Biointerfaces* 75, 1–18 (2010).
- 40. Singh, Ř. & Lillard, J. W. Nanoparticle-based targeted drug delivery. Experimental and molecular pathology 86, 215–223 (2009).
- Paciotti, G. F., Kingston, D. G. & Tamarkin, L. Colloidal gold nanoparticles: a novel nanoparticle platform for developing multifunctional tumor-targeted drug delivery vectors. *Drug development research* 67, 47–54 (2006).
- 42. Vivero-Escoto, J. L., Slowing, I. I., Wu, C.-W. & Lin, V. S.-Y. Photoinduced intracellular controlled release drug delivery in human cells by gold-capped mesoporous silica nanosphere. *Journal of the American Chemical Society* 131, 3462–3463 (2009).
- 43. Kim, S. B., Lee, T. H., Yoon, I., Shim, Y. K. & Lee, W. K. Gold Nanorod-Photosensitizer Complex Obtained by Layer-by-Layer Method for Photodynamic/Photothermal Therapy *In Vitro. Chemistry-An Asian Journal* 10, 563–567 (2015).
- 44. Holler, N. et al. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. *Nature immunology* 1, 489-495 (2000).
- 45. Degterey, A. et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nature chemical biology 1, 112–119 (2005).
- 46. Fulda, S. InSeminars in cell & developmental biology. 51–56 (Elsevier).
- 47. Su, Z., Yang, Z., Xie, L., DeWitt, J. & Chen, Y. Cancer therapy in the necroptosis era. Cell death and differentiation 23, 748 (2016).
- 48. Liu, Y. et al. Synergistic Immuno Photothermal Nanotherapy (SYMPHONY) for the Treatment of Unresectable and Metastatic Cancers. Scientific reports 7, 8606 (2017).

#### Acknowledgements

This study was supported by grants from Natural Science Foundation of China (NSFC, No. 81673009, 81660274), Jiangxi Provincial Natural Science Foundation (20161BBG70061, 20151BAB205060), and Canadian Institutes of Health Research (CIHR).

# **Author Contributions**

All the authors are contributed to this manuscript. Planned experiments: Y.Z., K.Y., W.M.; Performed experiments Y.Z., X.Z., W.H., Y.L., Y.C., S.P.; Analyzed data: Y.Z., J.X., R.L., K.Y., W.M., N.Z.; Wrote the paper: Y.Z., R.J., W.M. All authors are assured that we met the criteria for authorship and all reviewed the manuscript.

# **Additional Information**

**Competing Interests:** The authors declare no competing interests.

**Publisher's note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <a href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</a>.

© The Author(s) 2018